Complications occurred more often in patients who were older than 75 (40.2% vs 21.9%; <i>P</i> = .0009), female (57.1% vs 38.6%; <i>P</i> = .003), obese (59.7% vs 33.3%; <i>P</i> < .001), hypertensive (96.1% vs 79.3%; <i>P</i> = .0005), who received a sheath >6F (32.4% vs 13%; <i>P</i> < .0001), intraoperative and postoperative anticoagulation (77.3% vs 32.7% and 52.1% vs 24.2%, respectively; <i>P</i> < .0001), and periprocedural P2Y12 inhibitors (48.7% vs 28%; <i>P</i> = .0005).
Examples of drugs developed as a result of targeting GPCRs mutated in disease include: calcimimetics and calcilytics, therapeutics targeting melanocortin receptors in obesity, interventions that alter GNRHR loss from the cell surface in idiopathic hypogonadotropic hypogonadism and novel drugs that might rescue the P2RY12 receptor congenital bleeding phenotype.